Beckman Coulter Announces Third Quarter 20...( Total Revenue Rises 6%; Clinical D...)

Total Revenue Rises 6%; Clinical Diagnostics Grows 9.4%; On Target to

Achieve Full Year Outlook

FULLERTON, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today third quarter ended September 30, 2007 results. Total revenue of $669 million was up 6.0% over third quarter 2006, on strong sales in clinical diagnostics partially offset by lower than expected sales of life science products. In constant currency, revenue increased 4.1%. Net earnings were $60.0 million, or $0.93 per fully diluted share. Adjusting for special items, net earnings were $49.5 million, or $0.77 per fully diluted share, an increase of 16.7% over prior year quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

Three Months Ended Nine Months Ended

September 30 September 30

2007 2006 % Chg 2007 2006 % Chg

Reported Results

Revenue (in millions) $669.0 $631.2 6.0% $1,972.3 $1,816.5 8.6%

Diluted Earnings

per Share $0.93 $0.74 25.7% $2.61 $1.95 33.8%

Adjusted Results *

Diluted Earnings

per Share $0.77 $0.66 16.7% $2.17 $1.85 17.3%

* Excludes special items as detailed in the Adjusted Condensed

Consolidated Statements of Earnings and Reconciliation of Non-GAAP

Adjustments.

Total rev
'/>"/>